Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: xcr600 who wrote (12451)	6/14/2003 11:22:14 AM
From: tsigprofit	Respond to of 48461

ARDM - news - up 44% Friday, and up more in AH trading: (I own a position - thanks!!) Aradigm shares rise 44 pct on insulin data, report FRIDAY, JUNE 13, 2003 5:17 PM - Reuters U.S. Company News LOS ANGELES, June 13 (Reuters) - Shares of Aradigm Corp. (ARDM) , which is developing with Danish pharmaceutical group Novo Nordisk <NOVOb.CO> an inhaled form of insulin, rose 44 percent on Friday after an analyst report said the companies will present promising data on the product at a medical meeting. Shares of Aradigm, based in Hayward, California, rose 82 cents to close at $2.68 on Nasdaq. Punk, Ziegel & Co. analyst Matt Kaplan repeated a "buy" recommendation on the stock, citing additional analysis of mid-stage trial data on the AERx pulmonary insulin system that will be presented this weekend at a meeting of the American Diabetes Association in New Orleans. Kaplan's report says he does not receive compensation for views or recommendations, but he does own a position in shares of Aradigm and investors should assume that Punk, Ziegel is or will be seeking a business relationship with the company. Abstracts scheduled for release at the conference include evaluation of patient compliance, evaluation of lung function after 12 weeks of treatment and analysis of physicians' perception of inhaled insulin, the analyst's report said. "It appears physicians believe an insulin delivery system like the AERx insulin system that avoids the need for injections and a system that incorporates electronic monitoring of a patients medication use would likely lead to higher rates of patient compliance," Kaplan said. A spokesman for Aradigm said the company will release the full trial results on Saturday. Aradigm and Novo Nordisk announced last September the launch of a pivotal stage 24-month study of the inhaled insulin system. The companies previously said the 12-week, Phase IIb trial of the product in 107 patients showed it is equivalent to injectable insulin in terms of safety and antibody formation. People with diabetes, a disease that prevents the body from properly using energy from food, need extra insulin to control blood sugar levels. Untreated, diabetes can lead to blindness, heart disease, amputations or other serious complications. It is the fifth leading cause of death by disease in the United States.